Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/18/2010WO2010018278A2 Composition comprising crystallisation inhibitory substances
02/18/2010WO2010018268A1 Novel (rs)-7- or 9-(1,2,3,5-tetrahydro-4,1-benzoxazepin-3-il)-7h or 9h-purines having antitumour activity
02/18/2010WO2010018233A1 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
02/18/2010WO2010018231A2 Salt of, and processes for the preparation of, 1-isopropyl-4-{[4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine
02/18/2010WO2010018217A2 Organic compounds for wound healing
02/18/2010WO2010018214A1 Pyrrolidinone derivatives useful for the treatement of psychotic and neurological disorders
02/18/2010WO2010018175A2 Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
02/18/2010WO2010018134A1 Novel adenine derivatives
02/18/2010WO2010018133A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
02/18/2010WO2010018132A1 Compounds
02/18/2010WO2010018131A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
02/18/2010WO2010018130A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
02/18/2010WO2010018113A2 Bi-aryl aminotetralines
02/18/2010WO2010018112A2 Monoaryl aminotetralines
02/18/2010WO2010018109A2 Substituted aminotetralines
02/18/2010WO2010018095A1 Salicylamide derivatives as nicotinic alpha 7 modulators
02/18/2010WO2010017996A1 Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine
02/18/2010WO2010017948A2 Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
02/18/2010WO2010017918A2 Amorphous ambrisentan
02/18/2010WO2010017917A1 Pharmaceutical formulation for lowering pulmonary blood pressure
02/18/2010WO2010017885A2 Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl- penta-2,4-dienoic acid as a cosmetic
02/18/2010WO2010017870A1 Bicyclic triazole derivatives for treating tumors
02/18/2010WO2010017827A1 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
02/18/2010WO2010017821A1 Coated tablets with a remaining degradation surface over the time8
02/18/2010WO2010017632A1 Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
02/18/2010WO2010017626A1 Compositions comprising terpene compounds for treating negative sensory phenomena
02/18/2010WO2010017623A1 Antimicrobial silver solutions
02/18/2010WO2010017613A1 Use of 5-hydroxy-2-hydroxymethyl- y -pyrone (hmp) as a leishmanicidal agent
02/18/2010WO2010017570A2 Pharmaceutical form comprising tetrahydrobiopterin
02/18/2010WO2009158374A3 Inhibitors of akt activity
02/18/2010WO2009157016A3 Compositions comprising extracts from boswellia serrata
02/18/2010WO2009155611A9 Compositions for the treatment of fibrotic diseases or conditions
02/18/2010WO2009155121A3 Inhibitors of pi3 kinase
02/18/2010WO2009155054A3 5-ht3 receptor modulators, methods of making, and use thereof
02/18/2010WO2009155017A3 Novel substituted azabenzoxazoles
02/18/2010WO2009154873A9 Use of novel lipid mediators to inhibit angiogenesis
02/18/2010WO2009154819A3 Treatment of inflammatory conditions and diseases with metal-thiols
02/18/2010WO2009153373A3 Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same
02/18/2010WO2009153346A3 Stabilization of amorphous drugs using sponge-like carrier matrices
02/18/2010WO2009150381A3 Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
02/18/2010WO2009150137A3 Pyrazine derivatives as epithelial sodium channel blockers
02/18/2010WO2009148218A3 Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient
02/18/2010WO2009144738A4 Medicinal applications of benzoic acid hydrazones synthesized on the basis of steroidal tigogenin
02/18/2010WO2009140341A3 Atorvastatin compositions
02/18/2010WO2009137534A3 Estrogenic extracts for use in treating vaginal and vulvar atrophy
02/18/2010WO2009137087A3 A method for preventing or alleviating the noxious effects resulting from toxicant exposure
02/18/2010WO2009135673A8 Compounds with glycidic structure active in the therapy of systemic and local inflammation
02/18/2010WO2009135000A3 Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
02/18/2010WO2009132351A9 Anti-sense microrna expression vectors
02/18/2010WO2009132313A3 Morphinan derivatives of organic and inorganic acids
02/18/2010WO2009132119A3 Substituted oxazolidinones
02/18/2010WO2009131957A3 Compounds, compositions and methods comprising oxadiazole derivatives
02/18/2010WO2009129509A3 Methods and compositions for treating post-operative pain comprising a local anesthetic
02/18/2010WO2009129453A3 Clonidine formulation in a polyorthoester carrier
02/18/2010WO2009129437A3 Methods and compositions for treating post-operative pain comprising clonidine
02/18/2010WO2009129260A3 Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
02/18/2010WO2009127398A3 Conjugated linoleic acid derivatives
02/18/2010WO2009126705A3 Induction of tumor hypoxia for cancer therapy
02/18/2010WO2009126606A3 Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using parp inhibitors
02/18/2010WO2009126444A3 Compositions for the treatment of neurodegenerative conditions and methods for the use thereof
02/18/2010WO2009124371A3 Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these
02/18/2010WO2009120801A3 Ikki inhibitor therapies and screening methods, and related ikki diagnostics
02/18/2010WO2009120697A3 Method and compositions for treatment of cancer
02/18/2010WO2009114870A3 Kinase inhibitors and methods of use
02/18/2010WO2009114826A3 Treatment systems and methods for renal-related diseases
02/18/2010WO2009105853A8 Pharmaceutical composition comprising racetam and carnitine and process for its preparation
02/18/2010WO2009083521A3 Antibacterial compositions comprising an antiseptic in combination with an antibiotic
02/18/2010WO2009080778A4 Preparations with rosehip extracts, and method of producing rosehip extracts
02/18/2010WO2009080432A3 Composition for treatment of tuberculosis
02/18/2010WO2009076602A8 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
02/18/2010WO2009062604A3 Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
02/18/2010WO2009047775A3 Polymorphs of esomeprazole salts
02/18/2010WO2009027506A3 Local topical administration formulations containing fipronil
02/18/2010WO2009024989A3 A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
02/18/2010WO2009013360A9 Novel fluorescent derivatives of polyamine, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumours
02/18/2010WO2009001364A3 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
02/18/2010WO2008134828A8 Tissue degeneration protection
02/18/2010WO2008119146A8 Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd
02/18/2010WO2008109825A3 Inducing immune-mediated tumor cell death
02/18/2010WO2007110876A3 Novel sulfonanilide derivatives, pharmaceutical compositions comprising the same and process thereof
02/18/2010WO2004099390A3 Molecules for disease detection and treatment
02/18/2010US20100042217 Spine distraction implant and method
02/18/2010US20100041827 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly
02/18/2010US20100041826 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly
02/18/2010US20100041769 Stable and ready-to-use oil-in-water propofol microemulsion
02/18/2010US20100041768 Composition and method of adipose cell differentiation inhibition
02/18/2010US20100041767 Stabilized compositions of volatile alkylating agents and methods of using thereof
02/18/2010US20100041766 Medthods, Devices And Formulations For Targeted Endobronchial Therapy
02/18/2010US20100041765 High concentration local anesthetic formulations
02/18/2010US20100041764 Therapeutic agent for diabetic neuropathy
02/18/2010US20100041763 Salicylamide derivatives as nicotinic alpha 7 modulators
02/18/2010US20100041762 Substituted fused-ring compounds for inflammation and immune-related uses
02/18/2010US20100041761 New halo active aromatic sulfonamide organic compounds and odor control uses therefor
02/18/2010US20100041760 Monoaryl aminotetralines
02/18/2010US20100041759 Multi-phase release potassium guaiacolsulfonate compositions
02/18/2010US20100041758 Adhesive preparation
02/18/2010US20100041757 N-aryl-hydroxyalkylidene-carboxamide compounds and their use
02/18/2010US20100041756 method of modulating b cell functioning
02/18/2010US20100041755 Fatty acid treatment for cardiac patients
02/18/2010US20100041753 Inhibition of biofilm formation